Alvotech (ALVO) Non-Current Assets (2021 - 2026)
Alvotech (ALVO) posted Non-Current Assets of $965.2 million for Q1 2026, up 5.71% on a QoQ basis from $913.1 million in Q4 2025, and up 22.71% year-over-year from $786.6 million in Q1 2025.
Alvotech (ALVO) Non-Current Assets (2021 - 2026) Analysis & Trends
Alvotech's Non-Current Assets history runs 6 years deep, the most recent figure standing at $965.2 million for Q1 2026.
- Quarterly Non-Current Assets rose 22.71% year-over-year to $965.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $965.2 million (up 22.71% YoY) and the FY2025 annual result came in at $913.1 million, up 19.14% from the prior year.
- Non-Current Assets was $965.2 million for Q1 2026 at Alvotech, up from $913.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $977.2 million in Q3 2025 and bottomed at $535.8 million in Q2 2022.
- A 5-year average of $775.5 million and a median of $775.8 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 30.4% — and 2024, when it climbed 1.47%.
- Alvotech's Non-Current Assets stood at $597.7 million in 2022, then climbed by 26.36% to $755.2 million in 2023, then grew by 1.47% to $766.4 million in 2024, then advanced by 19.14% to $913.1 million in 2025, then climbed by 5.71% to $965.2 million in 2026.
- Business Quant data shows ALVO's Non-Current Assets at $965.2 million in Q1 2026, $913.1 million in Q4 2025, and $977.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 965.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 965.19 Mn |
| Dec 31, 2025 | 913.08 Mn |
| Sep 30, 2025 | 977.17 Mn |
| Jun 30, 2025 | 883.29 Mn |
| Mar 31, 2025 | 786.59 Mn |
| Dec 31, 2024 | 766.38 Mn |
| Sep 30, 2024 | 800.34 Mn |
| Jun 30, 2024 | 783.29 Mn |
| Mar 31, 2024 | 768.34 Mn |
| Dec 31, 2023 | 755.25 Mn |
| Jun 30, 2023 | 698.75 Mn |
| Mar 31, 2023 | 626.32 Mn |
| Dec 31, 2022 | 597.71 Mn |
| Jun 30, 2022 | 535.84 Mn |
| Dec 31, 2021 | 478.16 Mn |